Volume 34, Issue 12 | December 2018

# An Overview of Medication-Related FDA Online Resources

Gregory W. Smith, Pharm D
The University of Louisiana at Monroe College of Pharmacy

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. The resources and information hosted on the FDA website are directed to a variety of audiences including consumers, industry representatives, health professionals, patients, researchers, and state and local officials. Topics covered include, but are not limited to, food safety, medications (for both humans and animals), biologics, medical devices, tobacco products, and toxicology research. This article will focus on medication-related resources available to healthcare providers.



### **Table of Contents** An Overview of Medication-Related Online Resources 1 **Pharmacy Facts** 3 Medicare and Medicaid Advantage Filing Guidelines New Medicaid Eligibility System Launch (LaMEDS) Provider Portal to Replace Facility Notification System Online Medicaid Provider Manual Chapter Revisions as of November 2018 5 Archived Medicaid Provider Manual Chapters as of November 2018 Remittance Advice Corner 6 For Information or Assistance 12

### FDA Databases and Resources for Healthcare Professionals

### **Drugs@FDA: FDA Approved Drug Products**

*Drugs@FDA* includes most of the drug products approved since 1939. The majority of patient information, labels, approval letters, reviews, and other information are available for drug products approved since 1998. Users can search by drug name, active ingredient, or application number, or browse to the drug name alphabetically listed. www.accessdata.fda.gov/scripts/cder/daf/

Drugs@FDA Express Mobile App available.

### **Drug Info Rounds**

*Drug Info Rounds* is a series of training videos for practicing clinical and community pharmacists. Drug Info Rounds is provided by pharmacists in the FDA's Center for Drug Evaluation and Research (CDER), Office of Communications (OCOMM), Division of Drug Information (DDI). The goal of this program is to provide important and timely drug information to pharmacists so they can help patients make better medication decisions. www.fda.gov/drugs/resourcesforyou/healthprofessionals/ucm211957.htm

### **Drug Safety Communications**

*Drug Safety Communications* connects consumers and healthcare professionals to important drug safety information. The most recent Drug Safety Communications from FDA are available, as well as links for Early Communications, Follow-Up Early Communications, Information for Healthcare Professional sheets, and Public Health Advisories issued prior to January 29th, 2010. You can also find drug specific information using the <u>Index to Drug-Specific Information</u>.

www.fda.gov/Drugs/DrugSafety/ucm199082.htm

### **Drug Shortages**

Manufacturers provide the FDA with most drug shortage information, and the agency works closely with them to prevent or reduce the impact of shortages. Shortage notifications and updates may be reported to the FDA at <a href="mailto:drugshortages@fda.hhs.gov">drugshortages@fda.hhs.gov</a>. Users are able to search the *Drug Shortage Database* and register for email notifications.

www.fda.gov/DrugS/DrugSafety/DrugShortages/default.htm

FDA Drug Shortages Mobile App available.

### FDA Adverse Event Reporting System (FAERS)

FAERS is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to the FDA, and is designed to support the post-marketing safety surveillance program for drug and therapeutic biologic products. The FAERS Public Dashboard is an interactive web-based tool that makes the data easier to query and produces user-friendly information and charts. For example, users can view a summary of adverse event reports received from 1968 to the present or for a specific timeframe. In addition, users can search on a product of interest within a specific timeframe.

 $\underline{www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm}$ 

### **Label Repository**

The drug labels (package inserts) and other drug-specific information in this repository represent the most recent drug listing information companies have submitted to the FDA. The repository is searchable by proprietary name, active ingredient, company name, NDC number, and application number. https://labels.fda.gov

### **Medication Guides**

Medication guides, which are handouts that come with many prescription medicines, are FDA-approved documents that address issues that are specific to particular drugs, and can help patients avoid serious adverse events. The FDA requires that Medication Guides be issued with certain prescribed drugs and biological products when the Agency determines that: 1) certain information is necessary to prevent serious adverse effects, 2) patient decision-making should be informed by information about a known serious side effect with a product, or 3) patient adherence to directions for the use of a product are essential to its effectiveness.

www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page

### MedWatch: The FDA Safety Information and Adverse Event Reporting Program

MedWatch alerts provide up-to-date safety information on human drugs, medical devices, vaccines and other biologics, dietary supplements, and cosmetics. The alerts contain actionable information that may impact clinical decisions for healthcare professionals and patients. This website is also used to voluntarily report adverse events that are observed or suspected for human medical products, including serious drug side effects, product use/medication errors, product quality problems, and therapeutic failures.

www.fda.gov/safety/medwatch/

### **National Drug Code (NDC) Directory**

Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. The FDA publishes and maintains the NDC Directory which is updated daily.

www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm

FDA NDC Express Mobile App available

Volume 34, Issue 12 | December 2018

### Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the FDA under the Federal Food, Drug, and Cosmetic (FD&C) Act. Approved drug products can be searched by active ingredient, proprietary name, applicant, application number, dosage form, route of administration or patent number. Drug products are considered therapeutic equivalents (TE) only if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and are expected to have the same therapeutic efficacy and safety profile when administered to patients under the conditions specified in the labeling. The TE evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes, the criteria, and how to use the Orange Book can be found in the *Frequently Asked Questions on the Orange Book* section. (www.fda.gov/Drugs/InformationOnDrugs/ucm114166.htm)

www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm

Orange Book Express Mobile App available

### **Patient Educational Resources**

The FDA has numerous online drug information resources available for patients, including *Medication Guides* and *Medline Plus*. In addition, providers can download or order printed copies of easy-to-read materials for their patients. Some of the topics include safe medication use, misuse of prescription pain relievers, and tips for parents when administering medication to a child.

www.fda.gov/Drugs/ResourcesForYou/Consumers/default.htm

### Recalls, Market Withdrawals, & Safety Alerts

The FDA works with industry and state agencies to publish press releases and other public notifications about recalls that may potentially present a significant or serious risk to the user of a product. Press releases older than 60 days are accessible in the Recall and Safety Alerts Archive. Additional safety information about human medical products can be found on the FDA's MedWatch page.

www.fda.gov/Safety/Recalls/default.htm#additional-info

### Risk Evaluation and Mitigation Strategies (REMS)

The FDA Amendments Act of 2007 gave the FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological agent outweigh its risks. A list of medications with historical and released REMS can be found in the REMS@FDA section.

www.accessdata.fda.gov/scripts/cder/rems/index.cfm

## Pharmacy Facts Program Updates from Louisiana Medicaid

Pharmacy Facts can also be found online at: <a href="http://ldh.la.gov/index.cfm/page/3036">http://ldh.la.gov/index.cfm/page/3036</a>.

### **November 26, 2018**

The conference call scheduled for Monday, November 26 has been cancelled and will be rescheduled for later this week. The purpose of the call is to address any questions or concerns regarding a draft state plan amendment shared with stakeholders last week. The draft represents LDH's commitment to addressing provider concerns with how Medicaid pays for pharmacy services, including ingredient cost and professional dispensing fee, together with single PDL implementation. LDH intends to begin the process of seeking federal approval of the proposed changes in early December.

### Medicare and Medicaid Advantage Filing Guidelines

A recent review of claims for either dual eligible Medicare Medicaid recipients and/or QMB only recipients revealed many claim filing errors. To help reduce the number of denied claims or rejected claim files, you should follow the guidelines listed below:

- Some claims for dual eligible recipients are being submitted electronically as <u>fee for service</u> Medicaid claims. Submitters must not add claims with Medicare Coverage indicated into an 837P file with a file extension of **.PHY.**
- Claims for dual eligible recipients for coinsurance/deductible consideration should not be sent to Molina
   UNLESS the claim has failed to crossover from Medicare. If that is the situation, then the claim MUST be
   filed HARDCOPY with Medicare EOBs and not submitted electronically. Same guidelines apply when
   adjusting Medicare claims.
- Claims for dual eligible recipients with Medicare Advantage coverage can be filed electronically; however, there are special requirements for the layout of these files. Providers must work with their clearinghouse or submitter to ensure that the correct procedures are being followed. Submitters should contact Molina EDI and arrange for testing prior to sending such claims to Production. Refer to articles on lamedicaid.com dated 1/31/18 and 4/24/18 for additional details. The 837 Companion Guides have Medicare Advantage claim examples included.
- Claims for dual eligible recipients with **denials** for certain services not covered under traditional Medicare Part B coverage may be filed electronically as fee for service claims. The Medicare denial reason(s) must meet criteria established by the Louisiana Department of Health (LDH) as there are some exceptions. Refer to previous articles on lamedicaid.com dated 5/16/17 and 1/31/18 for details on how to file this claim type.

### **New Medicaid Eligibility System Launch (LaMEDS)**

The Medicaid Customer Service Hotline receives a large number of application status checks daily from providers. Due to the expected increase in call volume and wait times with the implementation of the new Medicaid eligibility system, LaMEDS, on November 13, 2018, CSU will begin **directing you to the MEVS system for verifying Medicaid**Eligibility effective immediately. For multiple status checks, you may complete the Provider Status Request Form located at <a href="http://dhhnet/dept/mva/MasterDocs/Provider%20Request%20Form.pdf">http://dhhnet/dept/mva/MasterDocs/Provider%20Request%20Form.pdf</a>.

If you have any problems with MEVS please contact Provider Relations at 1-800-473-2783 or <u>providerrelations@la.gov</u> for assistance.

Other helpful numbers: Provider Enrollment @ 1-225-216-6370 Claims – 1-800-473-2783 Website Issues – 1-877-598-8753

### **Provider Portal to Replace Facility Notification System**

Louisiana Medicaid's current Facility Notification System (FNS) will be made obsolete with the launch of a new eligibility and enrollment (E&E) system, scheduled to launch in December 2018.

The new E&E system includes a provider portal, which replaces the existing FNS as the means for provider, hospital and support coordination agency (SCA) representatives to submit forms for Medicaid to process. Updated security requires all current FNS users to re-register in the new system. An authorization check will be implemented for new user requests. Providers will need to appoint an individual who will be responsible for confirming new user access requests on behalf of the provider.

The last day to submit new forms in the FNS is Nov. 6, 2018. Providers should not submit new forms after this date and wait until the new provider portal is live (scheduled for Nov. 13). The last day to save lists of previous forms submitted is Nov. 7. FNS will not be available after the launch of the new E&E system.

Training videos are available to providers that introduce the basics of the provider portal. To learn how to manage information from a personal account or provider's profile, visit: http://ldh.la.gov/LaMEDSAccessProviderPortal. To learn how to submit, finish or view forms, visit: http://ldh.la.gov/LaMEDSProviderFormEntry. If you have questions, please contact msmcomm@la.gov.

Online Medicaid Provider Manual Chapter Revisions as of November 2018					
Manual Chapter	Section(s)	Date of Revision(s)			
Behavioral Health Services	<ul> <li>2.3 Outpatient Services – Outpatient Therapy by Licensed Practitioners</li> <li>2.4 Addiction Services</li> </ul>	11/27/18			
Dental Services	16.5 EPSDT – Covered Services	11/27/18			
Home Health Services	23.0 Overview 23.1 Description of Services 23.2 Services Limitations 23.3 Beneficiary Requirements 23.4 Provider Requirements 23.5 Prior Authorization 23.6 Claims Related Information Appendix A Regulatory Requirements (OASIS) Appendix D Contact/Referral Information Appendix E UB-04 Form and Instructions	11/28/18			
Hospital Services	<ul><li>25.2 Inpatient Services</li><li>25.3 Outpatient Services</li></ul>	11/07/18			
Intermediate Care Facilities for Individuals with Intellectual Disabilities	26.12 Cost Reports	11/28/18			
Professional Services	5.1 Covered Services	11/01/18			

Archived Online Medicaid Provider Manual Chapter Revisions as of November 2018					
Manual Chapter	Section(s)	Date of Omission(s)			
Behavioral Health Services	<ul> <li>2.3 Outpatient Services – Outpatient Therapy by Licensed Practitioners</li> <li>2.4 Addiction Services</li> </ul>	11/27/18			
Dental Services	16.5 EPSDT – Covered Services	11/27/18			
Home Health Services	23.0 Overview 23.1 Description of Services 23.2 Services Limitations 23.3 Beneficiary Requirements 23.4 Provider Requirements 23.5 Prior Authorization 23.6 Claims Related Information Appendix A Regulatory Requirements (OASIS) Appendix D Contact/Referral Information Appendix E UB-04 Form and Instructions	11/28/18			
Hospital Services	<ul><li>25.2 Inpatient Services</li><li>25.3 Outpatient Services</li></ul>	11/07/18			
Intermediate Care Facilities for Individuals with Intellectual Disabilities	26.12 Cost Reports	11/28/18			
Professional Services	5.1 Covered Services	11/01/18			

### **Remittance Advice Corner**

### **Attention Professional and Independent Laboratory Providers**

Reimbursement for Lynch Syndrome and Familial Adenomatous Polyposis (FAP) Genetic Testing Effective with dates of service January 1, 2019 and forward, Louisiana Medicaid will reimburse genetic testing for Lynch Syndrome and FAP.

In fee for service (FFS) Medicaid Genetic testing for Lynch Syndrome and FAP must be approved by the fiscal intermediary's Prior Authorization Unit (PAU). Information regarding this policy, medical necessity criteria for coverage and the required documentation is forthcoming, and will be found at <a href="https://www.lamedicaid.com">www.lamedicaid.com</a> under the Provider Manuals link within the Professional Services Manual.

Please contact the appropriate Managed Care Organization if there are questions concerning their policies and prior authorization process. In addition, questions regarding FFS Medicaid should be directed to Molina Provider Relations at (800) 473-2783 or (225) 924-5040.



### **Changes for Providers Using Facility Notification System**

The implementation of the state's new Medicaid eligibility and enrollment (E&E) system, is scheduled to go-live in mid-November 2018. The E&E system includes a Provider Portal, which <u>replaces the current Facility Notification System</u> (FNS) and allows provider, hospital and support coordination agency (SCA) representatives to submit forms for Medicaid to process. All current representatives authorized to submit forms in FNS will be <u>required to re-register in</u> the new system.

Training videos are available to providers that show how to register with the new system and introduce the basics of how to operate in the new Provider Portal. To learn how to manage information from a personal account or provider's profile, visit: <a href="http://ldh.la.gov/LaMEDSAccessProviderPortal">http://ldh.la.gov/LaMEDSProviderPortal</a>. To learn how to submit, finish or view forms, visit: <a href="http://ldh.la.gov/LaMEDSProviderFormEntry">http://ldh.la.gov/LaMEDSProviderFormEntry</a>.



### **Attention Providers of Preventive Medicine Visits**

### **Amendment to Louisiana Medicaid policy**

Effective for dates of service on or after December 1, 2018, Louisiana Medicaid will reimburse for one well-woman gynecological examination per calendar year for women aged 21 and over, when performed by a primary care provider or gynecologist. This is in addition to the current service provision of one preventive medicine visit for adults aged 21 years and older.

These service changes are in effect to allow women to receive the necessary primary care and gynecological components of their annual preventive screening visits. This additional component is not to facilitate duplicative services. Providers should continue to bill with the appropriate preventive medicine CPT codes, with the visit reflecting the specific medical nature of the service.

Questions regarding this message and fee-for-service claims should be directed to Molina Provider Relations at (800) 473-2783 or (225) 924-5040.

Questions related to managed care claims should be directed to the appropriate Managed Care Organization (MCO).



### **Attention Durable Medical Equipment Providers**

### **Durable Medical Equipment (DME) Coverge of Breast Pumps**

Effective for dates of service January 1, 2019, double electric breast pumps will be covered equipment without prior authorization. Recipients must present with a prescription for the breast pump and documentation of infant delivery to a DME provider. Louisiana Medicaid will only provide coverage for the personal-use, double electric breast pumps. Hospital grade, manual, or single breast pumps will **not** be covered. Nursing mothers will be eligible for one breast pump per delivery within a three (3) year period

Additionally, Medicaid will cover the appropriate breast pump supplies once every 180 days. A prescription for the supplies will be required.

Medicaid will allow replacement of breast pumps purchased within the past three (3) years from the date of request and after expiration of manufacturer's warranty. Replacement and warranty is subject to policy in the Durable Medical Equipment provider manual.

Questions regarding this message and fee for service claims should be directed to Molina Provider Relations at (800) 473-2783 or (225) 924-5040.

Questions regarding managed care claims should be directed to the appropriate managed care organization.



### **Reimbursement Changes for Physician-Administered Drugs**

### **Medicare Crossover Claim Adjustments**

Louisiana Medicaid has recently revised the reimbursement methodology for physician-administered drugs in a physician office setting effective with dates of service July 1, 2018.

Fee-for-service (FFS) Medicare crossover claims previously processed for physician-administered drugs (J-codes) or payable vaccines beginning with date of service July 1, 2018 have been adjusted/recycled as appropriate based on the updated reimbursement rate.

Providers can expect to see the results of this process as it applies to Medicare crossover claims on the remittance advice of October 30, 2018.

This action will affect Professional Services, Take Charge Plus and applicable Immunization claims.

Please contact Molina Provider Relations at (800) 473-2783 or (225) 924-5040 if there are questions related to this matter for FFS claims. Questions related to the Healthy Louisiana managed care organizations' updates should be directed to the specific health plan.



#### **Attention Providers Of Home Health Services**

Louisiana Medicaid has implemented changes required by The Centers for Medicare and Medicaid Services (CMS) in accordance with 42 CFR 440.70 for home health services, and in line with Medicaid State Plan updates.

Effective December 1, 2018 Louisiana Medicaid Fee for Service beneficiaries aged 21 and over will now require Prior Authorization (PA) for skilled nursing and home health aide services.

In addition, the following requirements must be followed:

- A face-to-face encounter between the patient and the physician or an allowed Non-Physician Provider (NPP) must occur no more than 90 days prior to, or 30 days after, admission to the home health agency.
- The orders for home health services must be written by the recipient's physician or the attending physician if the recipient is prescribed home health services for a post-acute or post sub-acute stay. See 42 CFR 440.70(f).
- Medicaid recipients do not have to be homebound in order to receive home health services, in accordance with 440.70(c) (1). Such services can be provided in a recipient's residential setting, which is defined as any non-institutional setting in which normal life activities take place.
  - o Services cannot be provided in a hospital, nursing facility, or Intermediate Care Facility for individuals with intellectual disabilities (ICF-IID), except as allowed in 42 CFR 440.70(c).

Medical supplies, equipment and appliances suitable for use in any setting in which normal life activities take
place are provided in accordance with physician review and other requirements as specified in 42 CFR
440.70(b)(3). A face-to-face encounter must be documented as occurring no more than 6 months prior to the
request.

Physical, Occupational and Speech Therapy, and Medical supplies, equipment and appliances under the Durable Medical Equipment program continue to be covered services in the home health program. The process for prior authorization for these services has not changed.

Documentation of a face-to-face encounter as detailed above must be kept in the recipient's record for ALL home health service related requests.

Providers for Fee for Service Medicaid recipients must submit all Initial and Reconsideration requests for prior authorization using the Electronic-PA (e-PA) process. The e-PA is a web application that provides a secure, web-based tool for providers to submit prior authorization requests and to view the status of previously submitted requests. The PA type for "Home Health Skilled Nursing and Home Health Aide Services for Ages 21 or Older" is PA type 18 (PA-18). For more information regarding e-PA, visit <a href="www.lamedicaid.com">www.lamedicaid.com</a> or call the Molina Prior Authorization Home Health Unit at 1-800-807-1320, then press Option 1.

Guidance on the new Prior Authorization process and the Physician Requirements for Ordering Home Health Services will be located at:

http://www.lamedicaid.com/provweb1/ProviderTraining/packets/2018ProviderTraining/2018PT Index.htm.

Specific information on the face-to-face requirement from CMS can be found in their final rule at this link: <a href="https://www.federalregister.gov/documents/2016/02/02/2016-01585/medicaid-program-face-to-face-requirements-for-home-health-services-policy-changes">https://www.federalregister.gov/documents/2016/02/02/2016-01585/medicaid-program-face-to-face-requirements-for-home-health-services-policy-changes</a>.

Questions regarding this message and fee for service claims should be directed to Molina Provider Relations at (800) 473-2783 or (225) 924-5040. Questions regarding Prior Authorizations should be directed to Molina Prior Authorization Home Health Unit at (800) 807-1320, then press Option 1.

Questions related to managed care should be directed to the appropriate Managed Care Organization (MCO).



### **Attention Home Health Providers**

The Department is changing the approval method for Home Health services available to Medicaid beneficiaries ages 21 and older. The following changes should be implemented effective December 1, 2018:

1. Skilled nursing and home health aide services for Medicaid beneficiaries aged 21 and older will now require prior authorization. The department is requesting Molina Medicaid Solutions adopt the attached "Home Health Prior Authorization Guidance for Recipients Aged 21 and Older" when prior authorizing these services.

For questions related to this request, please contact Helen Prett at (225) 342-7476.



### **Physician Requirements For Ordering Home Health Services**

The Centers for Medicare and Medicaid Services (CMS) requires a face-to-face encounter between a beneficiary and their certifying physician, or an allowed non-physician practitioner, to occur no sooner than 90 days prior to the start of home health services, or no later than 30 days after the start of home health services.

It is the responsibility of the home health agency to acquire the face-to-face encounter documentation and submit it to Molina, as soon as possible for both emergent and non-emergent home health services requests.

Any of the following will be accepted by the Molina Prior Authorization Unit (PAU) as evidence of a face-to-face encounter between a physician and the beneficiary, or an allowed non-physician practitioner and the beneficiary:

- A written and dated statement on the certifying physician's letterhead or prescription pad attesting to a face-to-face encounter between the physician and the beneficiary or an allowed non-physician practitioner and the beneficiary;
- The home health agency's face-to-face encounter form that the home health agency requires the beneficiary's certifying physician to complete as a routine business practice

If the face-to-face encounter is between an allowed non-physician practitioner and the beneficiary, the certifying physician must co-sign the document.

If the recipient was seen by a hospitalist or an attending physician in an acute or post-acute setting, the beneficiary's certifying physician must co-sign that the encounter occurred.

NOTE: Documentation of a face-to-face encounter must be kept in the recipient's record for ALL home health service related requests.

Questions regarding this message and fee for service claims should be directed to Molina Provider Relations at (800) 473-2783 or (225) 924-5040. Questions regarding Prior Authorizations should be directed to Molina Prior Authorization Home Health Unit at (800) 807-1320, then press Option 1.

Questions related to managed care should be directed to the appropriate Managed Care Organization (MCO).



### **Attention FOHCs and RHC Providers**

## Amendment to Medicaid Methodology of Reimbursement for Long- Acting Reversible Contraceptives to FQHCs and RHCs

Effective January 1, 2019 Louisiana Medicaid will reimburse for long-acting reversible contraceptives (LARCs) separate from the prospective payment system (PPS) rate to FQHCs and RHCs.

Reimbursement shall be separate from the FQHC and RHC PPS rate and will be the lesser of the Durable Medical Equipment fee for service rate on file or the actual acquisition cost (AAC), for entities participating in the 340B program.

Questions regarding this message and fee for service claims should be directed to Molina Provider Relations at (800) 473-2783 or (225) 924-5040.

Updates to Healthy Louisiana related policy, systems and claims processing changes are plan specific and are the responsibility of each health plan. For questions regarding Healthy Louisiana updates and prior authorization requirements, please contact the appropriate health plan



### **Attention Durable Medical Equipment Providers**

### **Long-Term Continuous Glucose Monitoring Device**

Effective January 1, 2019, Louisiana Medicaid will reimburse for long-term continuous glucose monitoring devices through the durable medical equipment program. Prior authorization is required and recipients must meet one of the following eligibility criteria:

- Diagnosis of type I diabetes with recurrent, unexplained, severe hypoglycemia (glucose levels <50 mg/di), or impaired hypoglycemia awareness that puts the recipient at risk or
- Pregnant recipient with poorly controlled type 1 diabetes evident by recurrent, unexplained hypoglycemic episodes, hypoglycemic unawareness, or postprandial hyperglycemia, or recurrent diabetic ketoacidosis.

**NOTE:** Louisiana Medicaid will not consider short term CGMs as a covered device. Updates to the Durable Medical Equipment provider manual are forthcoming.

Questions regarding fee for service Medicaid should be directed to Molina Provider Relations at (800) 473- 2783 or (225) 924-5040.

Questions regarding managed care claims should be directed to the appropriate Managed Care Organization.



For Information or Assistance, Call Us!				
Provider Enrollment	(225)216-6370	General Medicaid Eligibility Hotline	1-888-342-6207	
<b>Prior Authorization:</b>		MMIS Claims	(225) 342-3855	
Home Health/EPSDT – PCS	1-800-807-1320	Processing		
Dental	1-866-263-6534	Resolution Unit		
	1-504-941-8206			
DME & All Other	1-800-488-6334			
	(225) 928-5263	MMIS/Recipient	(225) 342-1739	
		Retroactive	1-866-640-3905	
Hospital Pre-Certification	1-800-877-0666	Reimbursement		
Provider Relations	1-800-473-2783	Medicare Savings	1-888-544-7996	
	(225) 924-5040	Program and		
		Medicaid Purchase Hotline		
REVS Line	1-800-776-6323			
	(225) 216-(REVS)7387			
Point of Sale Help Desk	1-800-648-0790	For Hearing	1-877-544-9544	
_	(225) 216-6381	Impaired		
		Pharmacy Hotline	1-800-437-9101	
		Medicaid Fraud	1-800-488-2917	

Hotline